Hasnyálmirigyrák: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• KRAS 66
• PD-1 39
• TP53 4
• mTOR 0
• PI3K 0
• STAT3 0
• PD-L1 20
• CLDN18 21
• EGFR 11
• RAS 17
• BRCA2 8
• AKT 0
• BRCA1 10
• ERK 0
• MAPK 1
• PARP 9
• STING 0
• HER2 13
• MYC 0
• YAP 0
• MEK 5
• PALB2 9
• CTLA-4 9
• VEGF 3
• AMPK 0
• ATM 3
• CD40 2
• CXCR4 0
• HIF-1 0
• JNK 0
• NRF2 0
• CDKN2A 3
• GLP-1 2
• NRAS 5
• PRMT5 6
• IL-6 0
• PPAR 0
• PTEN 0
• BCL-2 0
• FAK 1
• IL-15 1
• JAK 0
• TROP2 3
• BRAF 2
• MET 2
• B7-H3 2
• CDK4/6 0
• CTNNB1 0
• FGFR 1
• HSP90 0
• HDAC 0
• KEAP1 1
• CD47 0
• METTL3 0
• MUC1 3
• AXL 1
• CCR5 0
• HER3 1
• HMGB1 1
• NTRK 1

1+ intézményből 1, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · F31

  Assessing autophagic dependencies in the context of RAS inhibition in pancreatic ductal adenocarcinoma

  Univ of North Carolina Chapel Hill· Chapel Hill, Egyesült Államok· 37 011 USD awarded in fiscal year 2026· until 2029. szept.

• FDA · R01

  Safety and Efficacy of a Multi-Tumor-Associated Antigen-Specific T Cell Therapy in Pancreatic Cancer Patients

  Marker Therapeutics, Inc.· Houston, Egyesült Államok· 645 493 USD awarded in fiscal year 2026· until 2030. aug.

• NIH NIAMS · R21

  Nuclear Receptors In Cancer Cachexia

  University of Texas Hlth Sci Ctr Houston· Houston, Egyesült Államok· 200 604 USD awarded in fiscal year 2026· until 2028. júl.

• NIH NCI · U01

  The role of circadian gene regulation in pancreatic cancer progression and immune evasion

  University of Rochester· Rochester, Egyesült Államok· 626 555 USD awarded in fiscal year 2026· until 2031. aug.

• NIH NIAMS · R56

  Mitochondrial permeability transition in cancer cachexia

  University of Florida· Gainesville, Egyesült Államok· 307 000 USD awarded in fiscal year 2026· until 2027. aug.

• European Commission (Horizon Europe) · HORIZON-ERC

  Immunity under Pressure: Mapping Compression Driven Tumor–Immune Rewiring to Potentiate Immunotherapy in Pancreatic Cancer (MechanoImmunoMap)

  University of Cyprus· Nicosia, Ciprus· EU contribution 1 500 000 EUR· until 2032. jan.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Glycoengineering for Immune Modulation in Precision Anti-Cancer Therapies (GlycoIMPACT)

  Universitat Wien· Wien, Ausztria· EU contribution 230 185 EUR· until 2028. dec.· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  Next-Generation Radiopharmaceuticals for Glioblastoma and Pancreatic Cancer: A 3D Perspective (radio3D)

  Agencia Estatal Consejo Superior de Investigaciones Cientificas· Madrid, Spanyolország· EU contribution 4 366 500 EUR· until 2030. dec.· 9 countries

• European Commission (Horizon Europe) · HORIZON-ERC

  Evoking anti-tumor immunity in pancreatic cancer (Evoke-PDAC)

  Deutsches Krebsforschungszentrum Heidelberg· Heidelberg, Németország· EU contribution 2 497 125 EUR· until 2031. dec.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-SE

  EXPLORING THE MECHANISM OF METASTASIS/DEVELOPMENT OF NEW TESTS TO ENROLL CIRCULATING TUMOR CELLS (CTCs) INTO CLINICAL PRACTICE (CTC4CLINIC)

  Panepistimio Patron· Rio Patras, Görögország· EU contribution 796 590 EUR· until 2030. dec.· 7 countries

10 of 849 running projects, newest first. Listed amounts together: 443,9 M USD + 177,8 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

Ebben a nézetben egy vizsgálat sem jelzi, hogy megosztaná a résztvevői adatokat.

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 50
• Organoids 47
• Mendelian Randomization Analysis 29
• CRISPR-Cas Systems 16
• Gene Expression Profiling 123
• Sequence Analysis, RNA 11
• Whole Genome Sequencing 3
• Exome Sequencing 10
• Proteomics 55
• Metabolomics 34
• Mass Spectrometry 10
• Flow Cytometry 32
• Immunohistochemistry 70
• Liquid Biopsy 30
• Circulating Tumor DNA 29
• Xenograft Model Antitumor Assays 302
• Positron-Emission Tomography 30
• Magnetic Resonance Imaging 117
• Machine Learning 58
• Deep Learning 55
• Cohort Studies 108
• Genome-Wide Association Study 24

• Primer exchange reaction-based dual-signal amplified nano-flow cytometry and fluorescence analysis of MUC1- positive exosomes.

  Talanta, 2026. júl.

• High-quality acinar cell isolation enables single-cell analysis of healthy and injured pancreas.

  Cell Rep Methods, 2026. ápr.

• Assessment of NK cell cytotoxicity induced by IL-15 based immunotherapy against cancer cells.

  Methods Cell Biol, 2026. ápr.

• Single-cell RNA sequencing and high-dimensional flow cytometry reveal distinct peripheral immune landscapes of type 1 autoimmune pancreatitis and pancreatic ductal adenocarcinoma.

  Clin Transl Med, 2026. ápr.

• Protocol for analyzing immune cell infiltration in 3D pancreatic heterotypic spheroids composed of tumor cells and cancer-associated fibroblasts.

  STAR Protoc, 2026. febr.

• Integrated single cell RNA sequencing and flow cytometry analysis identifies elevated S100A6+ and S100A8+ myeloid subsets in pancreatic ductal adenocarcinoma.

  Clin Immunol, 2026. jan.

• Single-Cell RNA Sequencing of Pancreatic Circulating Tumor Cells.

  Methods Mol Biol, 2026. jan.

• Bone Marrow Metastasis from a Pancreatic Neuroendocrine Tumor: Morphologic Mimicry of Acute Leukemia.

  Clin Lab, 2025. dec.

• Investigation of the synergistic effect of metformin and FX11 on PANC-1 cell lines.

  Biol Res, 2025. márc.

• Classical and atypical resistance of cancer cells as a target for resveratrol.

  Oncol Rep, 2016. júl.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.